86,243 results match your criteria transplant rejection


Lung transplantation in the septuagenarian can be successfully performed though long-term results impacted by diseases of aging.

Clin Transplant 2022 Jan 15:e14593. Epub 2022 Jan 15.

Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.

Background: Advanced age is considered a risk factor for lung transplantation (LTX). We sought to evaluate the long-term outcomes of LTX in the septuagenarian.

Methods: LTX recipients in the UNOS transplant registry (May 1, 2005 to June 12, 2020) were stratified into 18-59, 60-69, and > = 70 years of age. Read More

View Article and Full-Text PDF
January 2022

Outcomes after heart transplantation in patients with cardiac sarcoidosis.

ESC Heart Fail 2022 Jan 15. Epub 2022 Jan 15.

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.

Background: The number of patients with sarcoidosis requiring heart transplantation (HT) is increasing. The aim of this study was to evaluate outcomes of isolated HT in patients with sarcoid cardiomyopathy and compare them to recipients with non-ischaemic restrictive or dilated cardiomyopathy.

Methods And Results: Adult HT recipients were identified in the UNOS Registry between 1990 and 2020. Read More

View Article and Full-Text PDF
January 2022

Peripheral blood eosinophilia as a marker of acute cellular rejection in lung transplant recipients.

J Heart Lung Transplant 2021 Dec 22. Epub 2021 Dec 22.

Lung Transplant Program, Hospital Universitario Puerta de Hierro, Madrid, Spain.

Previous studies in solid organ transplantation have shown a relationship between circulating eosinophil (EOS) counts and the presence of acute cellular rejection (ACR). However, the relationship between this potential biomarker and ACR in lung transplant (LTx) patients remains unclear.

Objective: To assess the association between EOS and the presence of acute cellular rejection in lung transplant recipients. Read More

View Article and Full-Text PDF
December 2021

Emergency Department Management of Pediatric Heart Transplant Recipients: Unique Immunologic and Hemodynamic Challenges.

J Emerg Med 2022 Jan 11. Epub 2022 Jan 11.

Division of Pediatric Cardiology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York. Electronic address:

Background: Since the first heart transplant in 1967, there has been significant progress in this field of cardiac transplantation. Approximately 600 pediatric heart transplants are performed every year worldwide. With the increasing number of pediatric heart transplant patients, and given the few tertiary care pediatric transplant centers, adult and pediatric emergency department (ED) providers are increasingly engaged in the care of pediatric heart transplant recipients in the ED. Read More

View Article and Full-Text PDF
January 2022

A Multifaceted Medication Adherence Promotion System to Reduce Late Kidney Allograft Rejection in Children and Young Adults.

Am J Kidney Dis 2022 Jan 11. Epub 2022 Jan 11.

Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Division of Transplantation, Department of Surgery, Northwestern Medicine, Chicago, Illinois. Electronic address:

View Article and Full-Text PDF
January 2022

Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.

Transplant Proc 2022 Jan 11. Epub 2022 Jan 11.

Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Background: One of the major barriers for long-term renal graft survival is considered to be calcineurin inhibitor nephrotoxicity, contributing to chronic graft dysfunction. Thus, recent immunosuppressive strategies are focused on regimens that can reduce or avoid exposure to calcineurin inhibitors. Herein, we carried out a small-scale pilot study to assess whether everolimus (EVR) with reduced-dose tacrolimus (Tac) is an acceptable immunosuppressive regimen for patients with de novo ABO-incompatible kidney transplant compared with mycophenolate mofetil (MMF) with standard-dose Tac. Read More

View Article and Full-Text PDF
January 2022

Long-term outcomes after heart transplantation using ex-vivo allograft perfusion in standard risk donors: A single center experience.

Clin Transplant 2022 Jan 14:e14591. Epub 2022 Jan 14.

Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Introduction: The Organ Care System (OCS) is an ex-vivo perfusion platform for donor heart preservation. Short/mid-term post-transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long-term outcomes following its use. Read More

View Article and Full-Text PDF
January 2022

Graft fibrosis over 10 to 15 years in pediatric liver transplant recipients: Multi-center study of paired, longitudinal surveillance biopsies.

Liver Transpl 2022 Jan 13. Epub 2022 Jan 13.

Department of Surgery, University of California San Francisco, San Francisco, CA, USA.

Background: Previous single-center, cross-sectional studies have reported a steep increase in the prevalence and severity of fibrosis through 10-15 years after pediatric liver transplantation. We report a multi-center study of paired surveillance biopsies in a contemporary cohort.

Methods: Children who underwent liver transplant at <6 years old and had paired surveillance liver biopsies were enrolled (n=78, 35% female, median 1. Read More

View Article and Full-Text PDF
January 2022

Long-term outcomes in pediatric patients who underwent living donor liver transplantation for biliary atresia.

Surgery 2022 Jan 10. Epub 2022 Jan 10.

Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke City, Tochigi, Japan.

Background: There is no consensus about long-term outcomes in patients with biliary atresia. We retrospectively reviewed the long-term outcomes in pediatric patients who underwent living donor liver transplantation for biliary atresia.

Methods: Between May 2001 and December 2020, 221 (73%) of 302 pediatric patients who underwent living donor liver transplantation had biliary atresia. Read More

View Article and Full-Text PDF
January 2022

Cytosporone B (Csn-B), an NR4A1 agonist, attenuates acute cardiac allograft rejection by inducing differential apoptosis of CD4+T cells.

Int Immunopharmacol 2022 Jan 10;104:108521. Epub 2022 Jan 10.

Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address:

CD4+T cell-mediated acute rejection remains a major factor that affects the early survival of transplanted organs post-transplantation. Here, we reveal that nuclear receptor subfamily 4 Group A member 1 (Nr4A1) was upregulated during cardiac allograft rejection and that the increased Nr4A1 was primarily localized in intragraft-infiltrating CD4+T cells. Nr4A1 acts as a transcription factor with an important role in CD4+T cell apoptosis, differentiation and T cell dysfunction, which indicates that Nr4A1 may play a critical role in transplant rejection. Read More

View Article and Full-Text PDF
January 2022

Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients.

J Appl Lab Med 2022 Jan 12. Epub 2022 Jan 12.

Laboratory of Applied Precision Omics (APO) and Genomic Research Alliance for Transplantation (GRAfT), National Institutes of Health, Bethesda, MD, USA.

Background: Prior studies demonstrate that donor-derived cell-free DNA (dd-cfDNA) in lung transplant recipients may serve as a marker of allograft injury for detecting allograft rejection and infection. Clinical interpretation of dd-cfDNA requires understanding its biological variation in stable lung transplant patients in order to identify abnormal results suggesting underlying allograft dysfunction. This study establishes the biological variation and reference change values (RCV) of dd-cfDNA in stable lung transplant recipients using an analytically validated assay with an established analytic coefficient of variation (CVA). Read More

View Article and Full-Text PDF
January 2022

Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?

Turk J Pediatr 2021 ;63(6):986-993

Department of Pediatric Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.

Background: Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells. Plasma based therapy (PT) was the mainstay of the treatment for aHUS for many years until the introduction of therapies targeting blockage of the complement system. The aim of this study was to evaluate patients with aHUS who had been treated with plasma based therapies alone. Read More

View Article and Full-Text PDF
January 2021

Graft function and pregnancy outcomes after kidney transplantation.

BMC Nephrol 2022 Jan 12;23(1):27. Epub 2022 Jan 12.

Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.

Background: After kidney transplantation, pregnancy and graft function may have a reciprocal interaction. We evaluated the influence of graft function on the course of pregnancy and vice versa.

Methods: We performed a retrospective observational study of 92 pregnancies beyond the first trimester in 67 women after renal transplantation from 1972 to 2019. Read More

View Article and Full-Text PDF
January 2022

RtNet: a deep hybrid neural networks for the identification of acute rejection and chronic allograft nephropathy after renal transplantation using multiparametric MRI.

Nephrol Dial Transplant 2022 Jan 10. Epub 2022 Jan 10.

Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Background: Reliable diagnosis of the cause of renal allograft dysfunction is of clinical importance. The aim of this study is to develop a hybrid deep learning approach for determining acute rejection (AR), chronic allograft nephropathy (CAN) and renal function in kidney-allografted patients by multimodality integration.

Methods: Clinical and MRI data of 252 kidney-allografted patients who underwent post-transplantation MRI between Dec 2014 and Nov 2019 were retrospectively collected. Read More

View Article and Full-Text PDF
January 2022

Application of machine learning in liver transplantation: a review.

Hepatol Int 2022 Jan 12. Epub 2022 Jan 12.

Ajmera Transplant Program, University Health Network, Toronto, ON, Canada.

Background: Machine learning (ML) has been increasingly applied in the health-care and liver transplant setting. The demand for liver transplantation continues to expand on an international scale, and with advanced aging and complex comorbidities, many challenges throughout the transplantation decision-making process must be better addressed. There exist massive datasets with hidden, non-linear relationships between demographic, clinical, laboratory, genetic, and imaging parameters that conventional methods fail to capitalize on when reviewing their predictive potential. Read More

View Article and Full-Text PDF
January 2022

International Survey of Clinical Monitoring Practices in Pancreas and Islet Transplantation.

Transplantation 2022 Jan 10. Epub 2022 Jan 10.

Division of Transplantation, Department of Surgery, University of California, San Francisco, San Francisco, CA. Department of Surgery, Multi-Organ Transplant Program, Toronto General Hospital, Toronto, ON. Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Division of Transplantation and Visceral Surgery, Department of Surgery, Geneva University Hospital, Geneva, Switzerland. Division of Transplantation, Department of Surgery, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL. Department of Medicine, St. Vincent's Hospital, St. Vincent's Institute of Medical Research, University of Melbourne, Melbourne, Victoria, Australia. Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. Department of Kidney Pancreas Transplantation, Instituto de Trasplantes y Alta Complejidad (ITAC - Nephrology), Buenos Aires, Argentina. Department of Medicine, Leiden University Medical Center, Leiden, Netherlands. Department of General, Visceral and Transplant Surgery, University Hospital Grosshadern, Ludwig Maximilian's University, Munich, Germany. Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway. Department of General Surgery, Wake Forest School of Medicine, Winston-Salem, NC.

Background: The long-term outcomes of both pancreas and islet allotransplantation have been compromised by difficulties in the detection of early graft dysfunction at a time when a clinical intervention can prevent further deterioration and preserve allograft function. The lack of standardized strategies for monitoring pancreas and islet allograft function prompted an international survey established by an International Pancreas and Islet Transplant Association/European Pancreas and Islet Transplant Association working group.

Methods: A global survey was administered to 24 pancreas and 18 islet programs using Redcap. Read More

View Article and Full-Text PDF
January 2022

Split-Combine Click-SELEX Reveals Ligands Recognizing the Transplant Rejection Biomarker CXCL9.

ACS Chem Biol 2022 Jan 12. Epub 2022 Jan 12.

Chemical Biology & Chemical Genetics, Life and Medical Sciences (LIMES) Institute, University of Bonn, Gerhard-Domagk-Str. 1, Bonn 53121, Germany.

Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. Read More

View Article and Full-Text PDF
January 2022

Outcomes of diabetic patients with end-stage heart failure listed for heart transplantation: A propensity-matched analysis.

Clin Transplant 2022 Jan 12:e14590. Epub 2022 Jan 12.

Division of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa, IA, United States.

Background: We investigated the current trends and outcomes of diabetic patients listed for heart transplants in the U.S. and provided a method for risk-stratification. Read More

View Article and Full-Text PDF
January 2022

miR-31, miR-155, and miR-221 expression profiles and their association with graft skin tolerance in a syngeneic vs. allogeneic murine skin transplantation model.

J Burn Care Res 2022 Jan 9. Epub 2022 Jan 9.

Laboratory of Connective Tissue, Centro Nacional de Investigación y Atención a Quemados, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico.

Grafting is the gold standard for the treatment of severe skin burns. Frequently, allogeneic tissue is the only transient option for wound coverage, but their use risks damage to surrounding tissues. MicroRNAs have been associated with acute rejection of different tissues/organs. Read More

View Article and Full-Text PDF
January 2022

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of Kidney Transplant Recipients.

Ann Transplant 2022 Jan 12;27:e934738. Epub 2022 Jan 12.

Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden.

BACKGROUND BK virus (BKV) infection after kidney transplantation leads to BKV-associated nephropathy (BKVAN) in up to 10% of recipients, and is associated with an increased risk of allograft dysfunction or loss. The objective of this study was to estimate the incidence of BKVAN and to analyze whether enhanced induction is associated with an increased risk of BKVAN, possibly justifying more intensive surveillance. MATERIAL AND METHODS This was a single-center retrospective cohort study. Read More

View Article and Full-Text PDF
January 2022

Posttransplant lymphoproliferative disorder in renal transplant recipients: Experience from a Tertiary Care Center.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):418-427

Department of Laboratory Science and Molecular Medicine, Army Hospital (Research and Referral), New Delhi, India.

Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal complications arising after solid organ or hematopoietic stem cell transplant. The most crucial factor in pathogenesis of PTLDs is either a primary infection with Epstein-Barr virus or reactivation of its latent state due to immune dysregulation. This complex pathobiology leads to a myriad of clinical manifestations due to uncontrolled lymphoproliferation that may be reactive, polymorphous or monomorphous. Read More

View Article and Full-Text PDF
January 2022

Plasma cell rich acute rejection: Risk factors, treatment and outcomes.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):387-397

Department of Pathology, Army Hospital (Research and Referral), New Delhi, India.

Plasma cell-rich rejection is a rare and poorly defined entity. Its treatment is not clearly defined and has universally poor prognosis. More data should be published from various transplant centers around the world to identify the treatment that has the best outcomes and to formulate treatment guidelines for these cases. Read More

View Article and Full-Text PDF
January 2022

Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.

Saudi J Kidney Dis Transpl 2021 Mar-Apr;32(2):348-354

Department of General Surgery, Division of Transplantation, Baskent University Ankara Hospital, Ankara, Turkey.

Intrapatient variability (IPV) in tacrolimus has been increasingly acknowledged as a risk factor for poor graft survival after kidney transplantation. Although past studies have mainly accounted for IPV in acute or chronic rejection states as due to underimmunosuppression, this is not yet clear. So far, tacrolimus IPV for BK virus-associated nephropathy (BKVN) and chronic calcineurin inhibitor toxicity (CNIT) has not been investigated. Read More

View Article and Full-Text PDF
January 2022

Macrophages in transplant rejection.

Authors:
Shaochen Yu Jian Lu

Transpl Immunol 2022 Jan 10;71:101536. Epub 2022 Jan 10.

Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei, Anhui 230022, China. Electronic address:

Transplant rejection is one of the primary factors leading to loss of allograft function, and macrophages are involved in allograft rejection. Macrophages polarize into different phenotypes according to stimulation by different external factors. Different types of macrophages play distinct roles in inflammation, tumors, and autoimmune diseases and are involved in transplant rejection. Read More

View Article and Full-Text PDF
January 2022

Higher levels of allograft injury in black patients early after heart transplantation.

J Heart Lung Transplant 2021 Dec 23. Epub 2021 Dec 23.

Genomic Research Alliance for Transplantation (GRAfT), Bethesda, Maryland; Laborarory of Applied Precision Omics (APO), Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland; Department of Medicine, Stanford University School of Medicine, Palo Alto, California. Electronic address:

Black patients suffer higher rates of antibody-mediated rejection and have worse long-term graft survival after heart transplantation. Donor-derived cell free DNA (ddcfDNA) is released into the blood following allograft injury. This study analyzed %ddcfDNA in 63 heart transplant recipients categorized by Black and non-Black race, during the first 200 days after transplant. Read More

View Article and Full-Text PDF
December 2021

Islet transplantation into brown adipose tissue can delay immune rejection.

JCI Insight 2022 Jan 11. Epub 2022 Jan 11.

Department of Microbiology, University of Alabama at Birmingham, Birmingham, United States of America.

Type 1 diabetes is an autoimmune disease characterized by insulin-producing beta-cell destruction. While islet transplantation restores euglycemia and improves patient outcomes, an ideal transplant site remains elusive. Brown adipose tissue (BAT) is a highly vascularized and anti-inflammatory microenvironment. Read More

View Article and Full-Text PDF
January 2022

Factors associated with follow-up outside a transplant center among pediatric kidney transplant recipients.

Pediatr Nephrol 2022 Jan 11. Epub 2022 Jan 11.

Department of Pediatrics, Brody School of Medicine at East Carolina University, 600 Moye Blvd, Greenville, NC, 27858, USA.

Background: Transfer of follow-up care after pediatric kidney transplantation (KTx) may jeopardize quality of care and patient outcomes. We sought to determine if minority status and socioeconomic factors were associated with increased likelihood of follow-up outside a transplant center, and whether this transition of care was associated with worse long-term graft and patient survival.

Methods: We performed an analysis of the United Network for Organ Sharing database, including children age < 18 years who received a kidney transplant between 2003 and 2018. Read More

View Article and Full-Text PDF
January 2022

Designer organs: The future of personalized transplantation.

Artif Organs 2022 Feb;46(2):180-190

Division of Transplantation, Department of Surgery, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Organ transplantation is the definitive treatment for end-stage solid organ diseases, yet biological and logistical barriers reduce the rate of successful organ transplants. As such, there is a need for gene therapy and gene modulation strategies in the organ transplantation setting to prevent rejection, expand the donor pool of available organs, and attenuate ischemia-reperfusion damage. As we are entering an era of "precision medicine," the organ transplant field is becoming equipped with the tools necessary to personalize and optimize organs designed specifically to withstand injurious pathways that occur during transplantation, such that the concept of "designer organs" will be a reality in the near future. Read More

View Article and Full-Text PDF
February 2022

Sex differences in the likelihood of pre-emptive living donor kidney transplantation, and outcomes after kidney transplantation in children and adolescents.

Pediatr Transplant 2022 Jan 10:e14224. Epub 2022 Jan 10.

Centre for Kidney Disease Research, University of Queensland, Brisbane, Queensland, Australia.

Background: Data on sex-based disparities in children with kidney failure and outcomes after kidney transplantation are relatively sparse. This study examined the association between sex differences and the odds of receiving a pre-emptive living donor kidney transplantation, and post-transplant outcomes in children and adolescents.

Methods: We studied all patients (aged <20 years) who commenced kidney replacement therapy (KRT) between 2002 and 2017 using data from the ANZDATA Registry. Read More

View Article and Full-Text PDF
January 2022

Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report.

Transplant Proc 2022 Jan 7. Epub 2022 Jan 7.

Moffitt Cancer Center, Tampa, Florida.

Checkpoint inhibitors decrease the progression of many cancers. However, the experience in immunosuppressed patients is limited, with reports of possible serious adverse events. We present a heart transplant recipient treated with pembrolizumab for metastatic melanoma who developed fatal rejection. Read More

View Article and Full-Text PDF
January 2022